Cabaletta Bio Capital Expenditures (CapEx) Growth & History (CABA)
Cabaletta Bio's capital expenditures (capex) was $1.2M for fiscal 2025.
View full Cabaletta Bio company overviewCabaletta Bio annual capital expenditures (capex) history
| Fiscal year | Period ended | Capital expenditures (CapEx) | Change | Growth |
|---|---|---|---|---|
| 2025 | 2025-12-31 | $1.2M | −$982,000 | −44.41% |
| 2024 | 2024-12-31 | $2.2M | $1.5M | +221.83% |
| 2023 | 2023-12-31 | $687,000 | −$1.8M | −71.99% |
| 2022 | 2022-12-31 | $2.5M | $1.3M | +110.38% |
| 2021 | 2021-12-31 | $1.2M | $531,000 | +83.62% |
| 2020 | 2020-12-31 | $635,000 | −$58,000 | −8.37% |
| 2019 | 2019-12-31 | $693,000 | — | — |
Cabaletta Bio quarterly capital expenditures (capex)
| Fiscal quarter | Period ended | Capital expenditures (CapEx) | Change | YoY change |
|---|---|---|---|---|
| Q2 2026 | 2026-06-30 | $0 | −$161,000 | — |
| Q1 2026 | 2026-03-31 | $0 | −$785,000 | — |
| Q4 2025 | 2025-12-31 | $205,000 | −$171,000 | −45.48% |
| Q3 2025 | 2025-09-30 | $78,000 | −$175,000 | −69.17% |
| Q2 2025 | 2025-06-30 | $161,000 | −$609,000 | −79.09% |
| Q1 2025 | 2025-03-31 | $785,000 | −$27,000 | −3.33% |
| Q4 2024 | 2024-12-31 | $376,000 | $191,000 | +103.24% |
| Q3 2024 | 2024-09-30 | $253,000 | $188,000 | +289.23% |
| Q2 2024 | 2024-06-30 | $770,000 | $713,000 | +1250.88% |
| Q1 2024 | 2024-03-31 | $812,000 | $432,000 | +113.68% |
| Q4 2023 | 2023-12-31 | $185,000 | −$131,000 | −41.46% |
| Q3 2023 | 2023-09-30 | $65,000 | −$1.0M | −94.05% |
| Q2 2023 | 2023-06-30 | $57,000 | −$841,000 | −93.65% |
| Q1 2023 | 2023-03-31 | $380,000 | $233,000 | +158.50% |
| Q4 2022 | 2022-12-31 | $316,000 | $165,000 | +109.27% |
| Q3 2022 | 2022-09-30 | $1.1M | $562,000 | +106.04% |
| Q2 2022 | 2022-06-30 | $898,000 | $510,000 | +131.44% |
| Q1 2022 | 2022-03-31 | $147,000 | $50,000 | +51.55% |
| Q4 2021 | 2021-12-31 | $151,000 | −$76,000 | −33.48% |
| Q3 2021 | 2021-09-30 | $530,000 | $368,000 | +227.16% |
| Q2 2021 | 2021-06-30 | $388,000 | $368,000 | +1840.00% |
| Q1 2021 | 2021-03-31 | $97,000 | −$129,000 | −57.08% |
| Q4 2020 | 2020-12-31 | $227,000 | −$46,000 | −16.85% |
| Q3 2020 | 2020-09-30 | $162,000 | $122,000 | +305.00% |
| Q2 2020 | 2020-06-30 | $20,000 | −$180,000 | −90.00% |
| Q1 2020 | 2020-03-31 | $226,000 | $46,000 | +25.56% |
| Q4 2019 | 2019-12-31 | $273,000 | — | — |
| Q3 2019 | 2019-09-30 | $40,000 | — | — |
| Q2 2019 | 2019-06-30 | $200,000 | — | — |
| Q1 2019 | 2019-03-31 | $180,000 | — | — |
Cabaletta Bio capital expenditures (capex) trends
Over the last five fiscal years, Cabaletta Bio's capital expenditures (capex) increased from $635,000 to $1.2M, a change of $594,000. The latest reported quarter, Q2 2026, shows $0.
What capital expenditures (CapEx) mean
Capital expenditures, commonly called CapEx, are cash investments in long-lived assets such as property, plants, equipment, infrastructure, and productive software. CapEx can support future growth or maintain existing operations, but it reduces current-period free cash flow.
SEC-reported capital expenditures
TickerStat standardizes cash payments for property, plant, equipment, and other productive assets reported in company SEC filings. When a filer reports separate qualifying CapEx components instead of a total, those components are combined for the same fiscal period. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review Cabaletta Bio source filings ↗